SOURCE: Masimo


October 30, 2013 16:05 ET

Masimo Reports Third Quarter 2013 Financial Results

IRVINE, CA--(Marketwired - Oct 30, 2013) - Masimo (NASDAQ: MASI) today announced its financial results for the third quarter ended September 28, 2013.

Q3 2013 Highlights (compared to Q3 2012):

  • Total revenue, including royalties, rose 10% to $131.4 million
  • Product revenue rose 11% to $124.5 million
  • Revenue from rainbow® products rose 9% to $12.0 million
  • SET® and rainbow® SET unit shipments rose 33% to 44,000
  • GAAP earnings per share rose 13% to $0.27

Masimo's total third quarter revenue, including royalties, rose 10% to $131.4 million, compared to $119.1 million for the third quarter of 2012. Third quarter 2013 product revenue rose 11% to $124.5 million, compared to $112.1 million for the third quarter of 2012. The company's worldwide direct product revenue grew 12% in the third quarter of 2013 and represented 85% of product revenue. OEM sales, which accounted for 15% of product revenue, rose 7% compared to the same period in 2012. Revenue from sales of Masimo rainbow products rose 9% to $12.0 million in the third quarter, compared to $11.0 million in the year-ago period. Third quarter 2013 rainbow revenue included $3.9 million in sales of total hemoglobin products. 

Net income for the third quarter of 2013 was $15.6 million, or $0.27 per diluted share, compared to net income of $13.8 million, or $0.24 per diluted share, in the third quarter of 2012. 

During the third quarter of 2013, the company shipped approximately 44,000 SET pulse oximetry and rainbow Pulse CO-Oximetry units, excluding handheld units, up 33% compared to approximately 33,100 in the same prior-year period. Masimo estimates its worldwide installed base as of September 28, 2013 to be 1,180,000 units, up 12% from 1,056,000 units as of September 29, 2012. 

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, "Masimo's ability to innovate technology that improves care, increases patient safety and lowers overall healthcare costs is the key success factor driving our strong third quarter results. As evidenced by our strong quarterly pulse oximetry and Pulse CO-Oximetry shipments, we are consistently expanding our customer base and, as a result, we are optimistic about our future."

As of September 28, 2013, Masimo's cash and cash equivalents were $91.7 million, compared to $71.6 million as of December 29, 2012. The change reflects primarily net cash generated from operations, offset by $19.8 million in cash used to repurchase one million shares of Masimo common stock in the first nine months of 2013.

2013 Financial Guidance
Based on favorable year-to-date results and the outlook for the remainder of 2013, Masimo is providing updated 2013 financial guidance for earnings per share. The company now expects 2013 GAAP earnings per share to be $1.16, compared to prior guidance of $1.14. The company's fiscal 2013 guidance for its other financial components, including total and product revenues, royalties, gross profit margins, operating expenses and tax rate components remains unchanged. Each of the components of Masimo's guidance set forth above is an estimate only and actual performance could differ.

Conference Call
Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. A live webcast of the conference call will be available online from the investor relations page of the company's corporate website at The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 87025552. After the live webcast, the call will be available on Masimo's website through November 13, 2013. In addition, a telephonic replay of the call will be available through November 13, 2013. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 87025552.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. And in 2012, Masimo acquired the assets of Spire Semiconductor, LLC, a maker of advanced light emitting diode (LED) and other advanced component-level technologies; and PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at

Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies and reduce the cost of care; expectations for full fiscal year 2013 total and product revenues, royalties, gross profit margins, operating expenses, tax rate and GAAP earnings per share; and demand for our technologies. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.

(unaudited) (in thousands)  
    September 28,
    December 29,
Current assets                
  Cash and cash equivalents   $ 91,717     $ 71,554  
  Accounts receivable, net of allowance for doubtful accounts     70,166       67,911  
  Royalties receivable     6,800       7,130  
  Inventories     59,460       47,358  
  Prepaid expenses     18,859       8,587  
  Deferred tax assets     12,003       12,911  
  Other current assets     2,928       3,896  
      Total current assets     261,933       219,347  
Deferred cost of goods sold     61,214       52,103  
Property and equipment, net     24,935       23,924  
Intangible assets, net     28,032       27,363  
Goodwill     22,959       22,824  
Deferred tax assets     21,506       22,363  
Other assets     7,190       8,022  
      Total assets   $ 427,769     $ 375,946  
Current liabilities                
  Accounts payable   $ 38,134     $ 27,033  
  Accrued compensation     28,506       25,021  
  Accrued liabilities     15,943       16,648  
  Income taxes payable     1,042       1,504  
  Deferred revenue     19,644       19,278  
  Current portion of capital lease obligations     122       55  
      Total current liabilities     103,391       89,539  
Deferred revenue     563       576  
Capital lease obligations, less current portion     233       60  
Other liabilities     9,683       10,103  
      Total liabilities     113,870       100,278  
  Masimo Corporation stockholders' equity:                
    Common stock     57       57  
    Treasury stock     (83,454 )     (63,664 )
    Additional paid-in capital     269,383       258,783  
    Accumulated other comprehensive income     4,425       3,542  
    Retained earnings     123,429       74,361  
      Total Masimo Corporation stockholders' equity     313,840       273,079  
  Noncontrolling interest     59       2,589  
      Total equity     313,899       275,668  
      Total liabilities and equity   $ 427,769     $ 375,946  
(unaudited) (in thousands, except per share amounts)  
    Three Months Ended   Nine Months Ended  
    September 28,
    September 29,
  September 28,
    September 29,
  Product   $ 124,522     $ 112,108   $ 382,725     $ 339,644  
  Royalty     6,925       6,961     22,086       21,428  
Total revenue     131,447       119,069     404,811       361,072  
Cost of goods sold     43,968       40,736     136,519       122,002  
Gross profit     87,479       78,333     268,292       239,070  
Operating expenses:                              
  Selling, general and administrative     53,090       48,260     159,536       142,381  
  Research and development     13,646       12,121     41,692       33,736  
Total operating expenses     66,736       60,381     201,228       176,117  
Operating income     20,743       17,952     67,064       62,953  
Non-operating income (expense)     (676 )     912     (3,240 )     (132 )
Income before provision for income taxes     20,067       18,864     63,824       62,821  
Provision for income taxes     4,581       5,301     17,288       15,724  
Net income including noncontrolling interest     15,486       13,563     46,536       47,097  
Net loss attributable to the noncontrolling interest     116       231     2,532       168  
Net income attributable to Masimo Corporation stockholders   $ 15,602     $ 13,794   $ 49,068     $ 47,265  
Net income per share attributable to Masimo Corporation stockholders:                              
  Basic   $ 0.28     $ 0.24   $ 0.86     $ 0.82  
  Diluted   $ 0.27     $ 0.24   $ 0.85     $ 0.81  
Weighted average shares used in per share calculations:                              
  Basic     56,501       57,201     56,727       57,507  
  Diluted     57,404       58,145     57,506       58,454  
(unaudited) (in thousands)  
    Nine Months Ended  
    September 28,
    September 29,
Cash flows from operating activities:                
  Net income including noncontrolling interest   $ 46,536     $ 47,097  
  Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities:                
    Depreciation and amortization     8,459       6,509  
    Share-based compensation     9,020       11,033  
    Loss on disposal of property and equipment     84       --  
    Provision for (benefit from) doubtful accounts     532       (5 )
    Provision for obsolete inventory     957       617  
    Provision for warranty costs     2,134       1,866  
    Provision for (benefit from) deferred income taxes     1,687       (319 )
    Income tax benefit from exercise of stock options granted prior to January 1, 2006     595       259  
    Excess tax deficit from share-based compensation arrangements     759       340  
    Realized foreign exchange loss on forward contracts     --       45  
    Changes in operating assets and liabilities:                
      Increase in accounts receivable     (2,773 )     (4,982 )
      (Increase) decrease in royalties receivable     330       (67 )
      Increase in inventories     (13,031 )     (1,700 )
      (Increase) decrease in deferred cost of goods sold     (9,100 )     160  
      Increase in prepaid expenses     (10,304 )     (2,888 )
      (Increase) decrease in other assets     1,777       (1,316 )
      Increase (decrease) in accounts payable     11,091       (2,730 )
      Increase in accrued compensation     3,544       2,344  
      Increase (decrease) in accrued liabilities     (2,807 )     820  
      Decrease in income taxes payable     (1,217 )     (419 )
      Increase in deferred revenue     354       2,490  
      Decrease in other liabilities     (417 )     (2,196) )
Net cash provided by operating activities     48,210       56,958  
Cash flows from investing activities:                
  Purchases of property and equipment     (6,910 )     (7,812 )
  Increase in intangible assets     (2,986 )     (2,904 )
  Cash paid for acquisitions     --       (37,399 )
Net cash used in investing activities     (9,896 )     (48,115 )
Cash flows from financing activities:                
  Repayments of capital lease obligations     (112 )     (12 )
  Proceeds from issuance of common stock     1,746       1,034  
  Excess tax deficit from share-based compensation arrangements     (759 )     (340 )
  Repurchases of common stock     (19,790 )     (26,268 )
  Net proceeds from settlement of forward contracts     --       88  
Net cash used in financing activities     (18,915 )     (25,498 )
Effect of foreign currency exchange rates on cash     764       (239 )
Net increase (decrease) in cash and cash equivalents     20,163       (16,894 )
Cash and cash equivalents at beginning of period     71,554       129,882  
Cash and cash equivalents at end of period   $ 91,717     $ 112,988  

Contact Information